The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma.

N P Graf; P Koelblinger; N Galliker; S Conrad; M Barysch; J Mangana; R Dummer; P F Cheng; S M Goldinger

doi:10.1111/jdv.15363

The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma.

N P Graf, P Koelblinger (Co-author), N Galliker, S Conrad, M Barysch, J Mangana, R Dummer, P F Cheng, S M Goldinger

Department of Dermatology and Allergology

Research output: Contribution to journal › Original Article › peer-review

16 Citations (Web of Science)

Original language	English
Pages (from-to)	686-692
Journal	JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
Volume	33
Issue number	4
DOIs	https://doi.org/10.1111/jdv.15363
Publication status	Published - 2019

Keywords

OPEN-LABEL
COMBINATION THERAPY
METASTATIC MELANOMA
IMPROVED SURVIVAL
BRAF INHIBITORS
MEK INHIBITION
VEMURAFENIB
DABRAFENIB
PHASE-3
MULTICENTER

Access to Document

10.1111/jdv.15363

Cite this

Graf, N. P., Koelblinger, P., Galliker, N., Conrad, S., Barysch, M., Mangana, J., Dummer, R., Cheng, P. F., & Goldinger, S. M. (2019). The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY , 33(4), 686-692. https://doi.org/10.1111/jdv.15363

Graf, N P ; Koelblinger, P ; Galliker, N et al. / The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma. In: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY 2019 ; Vol. 33, No. 4. pp. 686-692.

@article{9f1e8132ebf146eeac243f0ec6288988,

title = "The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma.",

keywords = "OPEN-LABEL, COMBINATION THERAPY, METASTATIC MELANOMA, IMPROVED SURVIVAL, BRAF INHIBITORS, MEK INHIBITION, VEMURAFENIB, DABRAFENIB, PHASE-3, MULTICENTER",

author = "Graf, {N P} and P Koelblinger and N Galliker and S Conrad and M Barysch and J Mangana and R Dummer and Cheng, {P F} and Goldinger, {S M}",

note = "Koelblinger: Paracelsus Med Univ, Dept Dermatol, Salzburg, Austria",

year = "2019",

doi = "10.1111/jdv.15363",

language = "English",

volume = "33",

pages = "686--692",

journal = "JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY ",

issn = "0926-9959",

publisher = "Wiley Verlag ",

number = "4",

}

Graf, NP, Koelblinger, P, Galliker, N, Conrad, S, Barysch, M, Mangana, J, Dummer, R, Cheng, PF & Goldinger, SM 2019, 'The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma.', JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY , vol. 33, no. 4, pp. 686-692. https://doi.org/10.1111/jdv.15363

The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma. / Graf, N P; Koelblinger, P (Co-author); Galliker, N et al.
In: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY , Vol. 33, No. 4, 2019, p. 686-692.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma.

AU - Graf, N P

AU - Koelblinger, P

AU - Galliker, N

AU - Conrad, S

AU - Barysch, M

AU - Mangana, J

AU - Dummer, R

AU - Cheng, P F

AU - Goldinger, S M

N1 - Koelblinger: Paracelsus Med Univ, Dept Dermatol, Salzburg, Austria

PY - 2019

Y1 - 2019

KW - OPEN-LABEL

KW - COMBINATION THERAPY

KW - METASTATIC MELANOMA

KW - IMPROVED SURVIVAL

KW - BRAF INHIBITORS

KW - MEK INHIBITION

KW - VEMURAFENIB

KW - DABRAFENIB

KW - PHASE-3

KW - MULTICENTER

U2 - 10.1111/jdv.15363

DO - 10.1111/jdv.15363

M3 - Original Article

C2 - 30468696

SN - 0926-9959

VL - 33

SP - 686

EP - 692

JO - JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

JF - JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

IS - 4

ER -

Graf NP, Koelblinger P, Galliker N, Conrad S, Barysch M, Mangana J et al. The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY . 2019;33(4):686-692. doi: 10.1111/jdv.15363